CoVaR-MS
An Observational Study to Evaluate Immune Response to Covid-19 Vaccines, Infections and Immune Treatments in People With Multiple Sclerosis
Sponsor study identifier
observational
240
1 country
1
Study Start
February 16, 2022
Actual (reported)Primary Completion
December 30, 2024
Actual (reported)Study Completion
December 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Coronavirus (Covid-19) has affected millions of people worldwide. Vaccines to prevent Covid-19 infection have been offered to reduce the risk of infection. While these vaccines have been offered to people with multiple sclerosis (MS), they have not been tested in these individuals. It is uncertain whether people with MS will develop protective antibodies after a Covid-19 vaccination and how long these antibodies will last. The investigators are planning to study the immune response to the full course of Covid-19 vaccine in people with MS (study group) and compare this to people without MS or immune suppression (control group).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 16, 2022
Actual (reported)March 2, 2022
Actual (reported)March 8, 2022
Actual (reported)December 30, 2024
Actual (reported)December 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Blood titres of Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche in MS patients compared with healthy volunteers 12 months from date of first dose of Covid-19 vaccine
Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche
12 months (+3 months) from date of first dose of Covid-19 vaccine
Blood titres of Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche in MS patients compared with healthy volunteers 18 months from date of first dose of Covid-19 vaccine
Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche
18 months (+3 months) from date of first dose of Covid-19 vaccine
T-SPOT® COVID SARS-CoV-2 test status in MS patients compared with healthy volunteers 12 months from date of first dose of Covid-19 vaccine
T-SPOT® COVID SARS-CoV-2 test status
12 months (+3 months) from date of first dose of Covid-19 vaccine
T-SPOT® COVID SARS-CoV-2 test status in MS patients compared with healthy volunteers 18 months from date of first dose of Covid-19 vaccine
T-SPOT® COVID SARS-CoV-2 test status
18 months (+3 months) from date of first dose of Covid-19 vaccine
Type and timing of DMT in MS patients
12 months (+3 months) from date of first dose of Covid-19 vaccine
Type and timing of DMT in MS patients
18 months (+3 months) from date of first dose of Covid-19 vaccine
Type and timing of Covid-19 vaccine in MS patients compared with healthy volunteers
12 months (+3 months) from date of first dose of Covid-19 vaccine
Type and timing of Covid-19 vaccine in MS patients compared with healthy volunteers
18 months (+3 months) from date of first dose of Covid-19 vaccine
Participant-reported PCR positive Covid-19 infection/s in MS patients compared with healthy volunteers
12 months (+3 months) from date of first dose of Covid-19 vaccine
30 patients with multiple sclerosis on Ocrelizumab (standard of care)
30 patients with multiple sclerosis on Natalizumab (standard of care)
30 patients with multiple sclerosis on Alemtuzumab (standard of care)
30 patients with multiple sclerosis on Tecfidera (standard of care)
Blood test 1 - At 12 months (+3months) from the date of 1st Covid-19 vaccine: Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres
There are two groups of participants in this study: 1. Multiple Sclerosis Patients (Study Group): 210 patients with multiple sclerosis, on and off disease modification treatment (DMT): * 180 patients on DMT, divided as follows: 30 patients on Ocrelizumab, 30 patients on Natalizumab, 30 patients on Alemtuzumab, 30 patients on Tecfidera, 30 patients on Fingolimod, 30 patients on Interferon * 30 patients off DMT 2. Healthy Volunteers (Control Group): 30 healthy volunteers
University Hospitals of North Midlands NHS Trust
Stoke-on-Trent, St4 6QG, United Kingdom
First Submitted
March 2, 2022
First Posted
March 8, 2022
Study Start
February 16, 2022
Actual (reported)Primary Completion
December 30, 2024
Actual (reported)Who Benefits Most From Cognitive Rehabilitation for Multiple Sclerosis?
30 patients with multiple sclerosis on Fingolimod (standard of care)
30 patients with multiple sclerosis on Interferon (standard of care)
30 patients with multiple sclerosis off disease modification treatment (DMT) (standard of care)
30 healthy volunteers
Blood test 2 - At 18 months (+3months) from the date of 1st Covid-19 vaccine: Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Study Completion
December 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
February 4, 2025
Record last verified: 2025-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: